Search

Your search keyword '"Lapa, Constantin"' showing total 1,167 results
Start Over Author "Lapa, Constantin"
1,167 results on '"Lapa, Constantin"'

10. Concept and feasibility of the Augsburg Longitudinal Plasma Study (ALPS) – a prospective trial for comprehensive liquid biopsy-based longitudinal monitoring of solid cancer patients

Author

Sommer Sebastian, Schmutz Maximilian, Hildebrand Kathrin, Schiwitza Annett, Benedikt Selinah, Eberle Maria, Mögele Tatiana, Sultan Aziz, Reichl Lena, Campillo Maria, Uhrmacher Luise, Nikolic Ana Antic, Bundschuh Ralph, Lapa Constantin, Kuhlen Michaela, Dintner Sebastian, Langer Angela, Märkl Bruno, Wendler Thomas, Tehlan Kartikay, Kröncke Thomas, Wahle Maria, Mann Matthias, Casadei Nicolas, Pogoda Michaela, Hummler Simone, Sax Irmengard, Schlesner Matthias, Kubuschok Boris, Trepel Martin, and Claus Rainer

Subjects
liquid biopsy, ctdna, longitudinal profiling, clonal evolution, spatial heterogeneity, translational research, Medical technology, R855-855.5
Abstract

Liquid biopsy (LBx) provides diagnostic, prognostic and predictive insights for malignant diseases and offers promising applications regarding tumor burden, tumor heterogeneity and clonal evolution.

Published
2024
Full Text
View/download PDF

22. Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis

Author

Luger, Anna-Luisa, König, Sven, Samp, Patrick Felix, Urban, Hans, Divé, Iris, Burger, Michael C., Voss, Martin, Franz, Kea, Fokas, Emmanouil, Filipski, Katharina, Demes, Melanie-Christin, Stenzinger, Albrecht, Sahm, Felix, Reuss, David E., Harter, Patrick N., Wagner, Sebastian, Hattingen, Elke, Wichert, Jennifer, Lapa, Constantin, Fröhling, Stefan, Steinbach, Joachim P., and Ronellenfitsch, Michael W.

Published
2022
Full Text
View/download PDF

26. PROLONGED AND INTENSE UPTAKE OF [177LU]LU-FAP-RTX IN MYOEPITHELIAL CARCINOMA: A CASE REPORT

Author

Souza, Stephan Pinheiro Macedo de, primary, Bundschuh, Ralph A., additional, Hügle, Martin, additional, Gäble, Alexander, additional, Rinscheid, Andreas, additional, Baldissera, Rafael, additional, Thome, Felipe, additional, Portugal, Rafael, additional, Ribeiro, Alan, additional, Portugal, Camila, additional, Quagliata, Adriana, additional, and Lapa, Constantin, additional

Published
2024
Full Text
View/download PDF

36. CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges

Author

Werner, Rudolf, additional, Haug, Alexander, additional, Buske, Christian, additional, Heidegger, Simon, additional, Illert, Anna L., additional, Bassermann, Florian, additional, Herhaus, Peter, additional, Buck, Andreas, additional, Duell, Johannes, additional, Topp, Max S, additional, Kraus, Sabrina, additional, Einsele, Hermann, additional, Lapa, Constantin, additional, Raderer, Markus, additional, Lenz, Georg, additional, Habringer, Stefan, additional, von Tresckow, Bastian, additional, and Keller, Ulrich, additional

Published
2024
Full Text
View/download PDF

37. Correction to: Value of PET imaging for radiation therapy

Author

Lapa, Constantin, Nestle, Ursula, Albert, Nathalie L., Baues, Christian, Beer, Ambros, Buck, Andreas, Budach, Volker, Bütof, Rebecca, Combs, Stephanie E., Derlin, Thorsten, Eiber, Matthias, Fendler, Wolfgang P., Furth, Christian, Gani, Cihan, Gkika, Eleni, Grosu, Anca-L., Henkenberens, Christoph, Ilhan, Harun, Löck, Steffen, Marnitz-Schulze, Simone, Miederer, Matthias, Mix, Michael, Nicolay, Nils H., Niyazi, Maximilian, Pöttgen, Christoph, Rödel, Claus M., Schatka, Imke, Schwarzenboeck, Sarah M., Todica, Andrei S., Weber, Wolfgang, Wegen, Simone, Wiegel, Thomas, Zamboglou, Constantinos, Zips, Daniel, Zöphel, Klaus, Zschaeck, Sebastian, Thorwarth, Daniela, and Troost, Esther G. C.

Published
2022
Full Text
View/download PDF

40. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients

Author

Fendler, Wolfgang Peter, Barrio, Martin, Spick, Claudio, Allen-Auerbach, Martin, Ambrosini, Valentina, Benz, Matthias, Bluemel, Christina, Grewal, Ravinder Kaur, Lapa, Constantin, Miederer, Matthias, Nicolas, Guillaume, Schuster, Tibor, Czernin, Johannes, and Herrmann, Ken

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Biomedical Imaging, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Bioengineering, Digestive Diseases, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Adult, Aged, False Positive Reactions, Female, Humans, Image Enhancement, Male, Middle Aged, Neuroendocrine Tumors, Observer Variation, Organometallic Compounds, Positron Emission Tomography Computed Tomography, Prospective Studies, Radiopharmaceuticals, Reproducibility of Results, Sensitivity and Specificity, neuroendocrine tumor, agreement, reproducibility, PET/CT, DOTATATE, interobserver, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

We evaluated observer agreement for 68Ga-DOTATATE PET/CT interpretations in patients with neuroendocrine tumor (NET).Methods68Ga-DOTATATE PET/CT was performed on 50 patients with known or suspected NET of the small bowel (n = 19), pancreas (n = 14), lung (n = 4), or other location (n = 13). The images were reviewed by 7 observers, who used a standardized interpretation approach. The observers were classified as having a low level of experience (

Published
2017

43. Biodistribution and radiation dosimetry of [99mTc]Tc-N4-BTG in patients with biochemical recurrence of prostate cancer.

Author

Rinscheid, Andreas, Gäble, Alexander, Wienand, Georgine, Dierks, Alexander, Kircher, Malte, Günther, Thomas, Patt, Marianne, Bundschuh, Ralph A., Lapa, Constantin, and Pfob, Christian H.

Subjects
SINGLE-photon emission computed tomography, RADIATION dosimetry, CANCER relapse, PROSTATE cancer, DISEASE relapse, PROSTATE, HOLMIUM, PANCREAS
Abstract

Background: In patients with prostate cancer (PCa), imaging with gastrin-releasing peptide receptor (GRPR) ligands is an alternative to PSMA-targeted tracers, particularly if PSMA expression is low or absent. [99mTc]Tc-N4-BTG is a newly developed GRPR-directed probe for conventional scintigraphy and single photon emission computed tomography (SPECT) imaging. The current study aims to investigate the safety, biodistribution and dosimetry of [99mTc]Tc-N4-BTG in patients with biochemical recurrence (BCR) of PCa. Results: No adverse pharmacologic effects were observed. Injection of [99mTc]Tc-N4-BTG resulted in an effective dose of 0.0027 ± 0.0002 mSv/MBq. The urinary bladder was the critical organ with the highest mean absorbed dose of 0.028 ± 0.001 mGy/MBq, followed by the pancreas with 0.0043 ± 0.0015 mGy/MBq, osteogenic cells with 0.0039 ± 0.0005 mGy/MBq, the kidneys with 0.0034 ± 0.0003 mGy/MBq, and the liver with 0.0019 ± 0.0004 mGy/MBq, respectively. No focal tracer uptake suggestive of PCa recurrence could be revealed for any of the patients. Conclusion: [99mTc]Tc-N4-BTG appears to be a safe diagnostic agent. Compared to GRPR-targeted PET tracers, this 99mTc-labelled SPECT agent could contribute to a broader application and better availability of this novel approach. Further research to assess its clinical value is warranted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology.

Author

Dreher, Niklas, Hahner, Stefanie, Fuß, Carmina T., Schlötelburg, Wiebke, Hartrampf, Philipp E., Serfling, Sebastian E., Schirbel, Andreas, Samnick, Samuel, Higuchi, Takahiro, Weich, Alexander, Lapa, Constantin, Rosenwald, Andreas, Buck, Andreas K., Kircher, Stefan, and Werner, Rudolf A.

Subjects
POSITRON emission tomography, IMAGE analysis, SMALL cell lung cancer
Abstract

Background: C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in various solid cancers and can be targeted by CXCR4-directed molecular imaging. We aimed to characterize the in-vivo CXCR4 expression in patients affected with solid tumors, along with a comparison to ex-vivo findings. Methods: A total 142 patients with 23 different histologically proven solid tumors were imaged with CXCR4-directed PET/CT using [68 Ga]Ga-pentixafor (total number of scans, 152). A semi-quantitative analysis of the CXCR4-positive tumor burden including maximum standardized uptake values (SUVmax) and target-to-background ratios (TBR) using blood pool was conducted. In addition, we performed histopathological staining to determine the immuno-reactive score (IRS) from patients' tumor tissue and investigated possible correlations with SUVmax (by providing Spearman's rho ρ). Based on imaging, we also assessed the eligibility for CXCR4-targeted radioligand therapy or non-radioactive CXCR4 inhibitory treatment (defined as more than five CXCR4-avid target lesions [TL] with SUVmax above 10). Results: One hundred three of 152 (67.8%) scans showed discernible uptake above blood pool (TBR > 1) in 462 lesions (52 primary tumors and 410 metastases). Median TBR was 4.4 (1.05–24.98), thereby indicating high image contrast. The highest SUVmax was observed in ovarian cancer, followed by small cell lung cancer, desmoplastic small round cell tumor, and adrenocortical carcinoma. When comparing radiotracer accumulation between primary tumors and metastases for the entire cohort, comparable SUVmax was recorded (P > 0.999), except for pulmonal findings (P = 0.013), indicative for uniform CXCR4 expression among TL. For higher IRS, a weak, but statistically significant correlation with increased SUVmax was observed (ρ = 0.328; P = 0.018). In 42/103 (40.8%) scans, more than five TL were recorded, with 12/42 (28.6%) exhibiting SUVmax above 10, suggesting eligibility for CXCR4-targeted treatment in this subcohort. Conclusions: In a whole-body tumor read-out, a substantial portion of prevalent solid tumors demonstrated increased and uniform [68 Ga]Ga-pentixafor uptake, along with high image contrast. We also observed a respective link between in- and ex-vivo CXCR4 expression, suggesting high specificity of the PET agent. Last, a fraction of patients with [68 Ga]Ga-pentixafor-positive tumor burden were rendered potentially suitable for CXCR4-directed therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT

Author

Bluemel, Christina, Krebs, Markus, Polat, Bülent, Linke, Fränze, Eiber, Matthias, Samnick, Samuel, Lapa, Constantin, Lassmann, Michael, Riedmiller, Hubertus, Czernin, Johannes, Rubello, Domenico, Bley, Thorsten, Kropf, Saskia, Wester, Hans-Juergen, Buck, Andreas K, and Herrmann, Ken

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Bioengineering, Prostate Cancer, Clinical Research, Urologic Diseases, Biomedical Imaging, Cancer, Aged, Aged, 80 and over, Antigens, Surface, Choline, Gallium Radioisotopes, Glutamate Carboxypeptidase II, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, choline-PET/CT, PSMA-PET/CT, prostate cancer, recurrence, restaging, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

PurposeInvestigating the value of Ga-PSMA-PET/CT in biochemically recurring prostate cancer patients with negative F-choline-PET/CT.Patients and methodsOne hundred thirty-nine consecutive patients with biochemical recurrence after curative (surgery and/or radiotherapy) therapy were offered participation in this sequential clinical imaging approach. Patients first underwent an F-choline-PET/CT. If negative, an additional Ga-PSMA-PET/CT was offered. One hundred twenty-five of 139 eligible patients were included in the study; 32 patients underwent additional Ga-PSMA-PET/CT. Patients with equivocal findings (n = 5) on F-choline-PET/CT and those who declined the additional Ga-PSMA-PET/CT (n = 9) were excluded. Images were analyzed visually for the presence of suspicious lesions. Findings on PET/CT were correlated with PSA level, PSA doubling time (dt), and PSA velocity (vel).ResultsThe overall detection rates were 85.6% (107/125) for the sequential imaging approach and 74.4% (93/125) for F-choline-PET/CT alone. Ga-PSMA-PET/CT detected sites of recurrence in 43.8% (14/32) of the choline-negative patients. Detection rates of the sequential imaging approach and F-choline-PET/CT alone increased with higher serum PSA levels and PSA vel. Subgroup analysis of Ga-PSMA-PET/CT in F-choline negative patients revealed detection rates of 28.6%, 45.5%, and 71.4% for PSA levels of 0.2 or greater to less than 1 ng/mL, 1 to 2 ng/mL, and greater than 2 ng/mL, respectively.ConclusionsThe sequential imaging approach designed to limit Ga-PSMA imaging to patients with negative choline scans resulted in high detection rates. Ga-PSMA-PET/CT identified sites of recurrent disease in 43.8% of the patients with negative F-choline PET/CT scans.

Published
2016

49. First Safety and Efficacy Data with the Radiohybrid177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer

Author

Dierks, Alexander, primary, Gäble, Alexander, additional, Rinscheid, Andreas, additional, Wienand, Georgine, additional, Pfob, Christian H., additional, Kircher, Malte, additional, Enke, Johanna S., additional, Janzen, Tilman, additional, Patt, Marianne, additional, Trepel, Martin, additional, Weckermann, Dorothea, additional, Bundschuh, Ralph A., additional, and Lapa, Constantin, additional

Published
2023
Full Text
View/download PDF

50. CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology

Author

Dreher, Niklas, primary, Hahner, Stefanie, additional, Fuß, Carmina T., additional, Schlötelburg, Wiebke, additional, Hartrampf, Philipp E., additional, Serfling, Sebastian E., additional, Schirbel, Andreas, additional, Samnick, Samuel, additional, Higuchi, Takahiro, additional, Weich, Alexander, additional, Lapa, Constantin, additional, Rosenwald, Andreas, additional, Buck, Andreas K., additional, Kircher, Stefan, additional, and Werner, Rudolf A., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results